Moxifloxacin Sanoswiss (Moxifloxacin)

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. This inhibition stops bacterial cell division, leading to a bactericidal effect against a broad range of Gram‑positive and Gram‑negative organisms.

The dosage regimen for Moxifloxacin Sanoswiss is determined by the prescribing clinician based on the specific infection, patient characteristics, and local guidelines. Patients should follow the exact dose and schedule provided by their healthcare professional.

Safety data for moxifloxacin in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified prescriber.

To request Moxifloxacin Sanoswiss, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive organisms and better activity against atypical respiratory pathogens compared with older fluoroquinolones like ciprofloxacin. Its pharmacokinetic profile allows once‑daily dosing, but safety considerations such as QT prolongation remain similar across the class.

Moxifloxacin Sanoswiss should be stored at ambient temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date.

Moxifloxacin Sanoswiss is administered orally, typically as a tablet taken with or without food. Patients should swallow the tablet whole with a full glass of water and avoid crushing or chewing it unless instructed otherwise by a healthcare professional.

Serious risks include tendon rupture, especially of the Achilles tendon, QT interval prolongation leading to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated diarrhea, and hepatic injury. Patients should seek immediate medical attention if they experience any of these events.

Moxifloxacin Sanoswiss is contraindicated in individuals with a known hypersensitivity to moxifloxacin or other fluoroquinolones. It should also be avoided in patients with a history of tendon disorders related to fluoroquinolone use, and used with extreme caution in those with significant cardiac arrhythmias or prolonged QT interval.